Product Information
BONSITY 560 MCG/2.24 ML PEN is a generic product labeled by Alvogen Inc., priced at $479.9511 per ML under NDC 47781085289. Its NADAC has been published 61 times since Aug 6, 2025.
FDA first approved this application on Oct 4, 2019.
Strength
250 ug/mL
Manufacturer
Alvogen Inc.NDC
47781085289
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
TERIPARATIDEApproval Type
New Drug (NDA)
FDA Application
NDA211939FDA Approved
10/4/2019
On Market Since
6/6/2025
Pharmacological Classes
Price Statistics
The NADAC for BONSITY 560 MCG/2.24 ML PEN has been published 61 times since Aug 6, 2025, and over the history we have for it it has declined 43.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $479.9511 per ML |
|---|---|
| All-time high | $846.0749 (Oct 15, 2025) |
| All-time low | $479.9511 (Sep 23, 2026) |
| 52-week high | $846.0749 |
| 52-week low | $479.9511 |
| Median price | $624.8910 |
| Average price | $635.7610 |
| Largest weekly change | -20.7% (Oct 22, 2025) |
| Weeks tracked | 61 |
| Tracking since | Aug 6, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alvogen Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
teriparatide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Parathyroid Hormone Analog class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BONSITY 560 MCG/2.24 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for BONSITY 560 MCG/2.24 ML PEN, manufactured by Alvogen Inc., is $479.9511 per ML (NDC 47781085289), effective Sep 30, 2026.
How has the price of BONSITY 560 MCG/2.24 ML PEN changed over time?
Over the history we have for it, the NADAC for BONSITY 560 MCG/2.24 ML PEN has declined 43.3%. It has been tracked across 61 weekly CMS publications since Aug 6, 2025.
What are the highest and lowest recorded NADAC prices for BONSITY 560 MCG/2.24 ML PEN?
Since Aug 6, 2025, the NADAC for BONSITY 560 MCG/2.24 ML PEN has ranged from a low of $479.9511 (Sep 23, 2026) to a high of $846.0749 (Oct 15, 2025), with a median of $624.8910 per ML.
Are there cheaper alternatives to BONSITY 560 MCG/2.24 ML PEN?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BONSITY 560 MCG/2.24 ML PEN in a comparable dosage form, but none are currently priced below it.
Who manufactures BONSITY 560 MCG/2.24 ML PEN?
BONSITY 560 MCG/2.24 ML PEN (NDC 47781085289) is labeled by Alvogen Inc., and CMS classifies it as a generic product.